Tag Archives: RSV

July, 2017

7 July
Experts Urge Action to Cut Child Deaths from Deadly Lung Virus

Vaccines to combat a virus that can lead to fatal lung infections are urgently needed to help prevent child deaths worldwide, research suggests. Experts report that more than 115,000 children under five are dying each year from complications associated with the infection, called Respiratory Syncytial Virus (RSV). Almost half of …
Share

3 March
Sanofi Pasteur and MedImmune Partner to Develop and Commercialize Respiratory Syncytial Virus Candidate

MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, today announced an agreement to develop and commercialise MEDI8897 jointly. MEDI8897 is a monoclonal antibody (mAb) for the prevention of lower respiratory tract illness (LRTI) caused by respiratory syncytial virus (RSV), the …
Share

9 April
MedImmune’s Respiratory Syncytial Virus Candidate Receives Fast Track Status from the FDA

Today, AstraZeneca’s biologics arm MedImmune announced that US health regulators have granted fast track designation for its respiratory syncytial virus (RSV) candidate. The company said that the US Food and Drug Administration (FDA) has granted Fast Track status for the development of MEDI8897, a high-potency, extended half-life monoclonal antibody (mAb). …
Share